Corporate Profile

Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The Company specializes in the development and manufacturing of medical devices and has been successfully accessing capital on the public markets as required to finance its operations to date. It is currently preparing for transition to a commercialization phase.

Miraculins began as a research and development company in 2002, with a focus on biomarker discovery. In June of 2008, the company shifted its focus to diagnostic asset development where it began to in-license and acquire diagnostic and risk assessment technologies that had completed early stage research and addressed significant unmet medical needs in the U.S., Canada, and global markets.

The company's lead technology programs - the Scout DS® Diabetes Screen and the PreVu®  Skin Cholesterol Test - screen for risk of diabetes and coronary artery disease respectively, without needles, blood draw, fasting or waiting. Patients with elevated test results are then recommended to see their physicians for follow-up.

The Company's business strategy includes leasing and selling its non-invasive medical devices and consumables to hospitals, clinics and physician's offices; providing retail testing through pharmacies/grocery chains; and delivering workplace health screenings. Scout DS® and PreVu® are Health Canada cleared and CE-Marked for the EU. PreVu® is also FDA cleared and the Company plans to file pre-submission documentation regarding the de novo classification of its Scout DS® device, as a next step in securing its marketing clearance in the United States.

The Miraculins management team is comprised of individuals with expansive experience in the management of biotechnology and public companies, and with proven track records in sales, marketing, communications, manufacturing, distribution and operations. The management team is complemented and supported by a board of directors with deep corporate, legal, financial, and media experience; a strong science and technology team of researchers, scientists, and engineers; and medical advisors comprised of physicians and clinicians.

The Company continues to explore new in-licensing and acquisition opportunities in areas where there are unmet clinical needs, while advancing its current technology programs.